Jove
Visualize
Contact Us

Related Experiment Videos

Repaglinide in combination therapy.

R Moses1

  • 1University of Wollongong, New South Wales, Australia. bmoses@uow.edu.au

Diabetes, Nutrition & Metabolism
|April 19, 2003
PubMed
Summary
This summary is machine-generated.

Repaglinide combined with metformin, NPH-insulin, or thiazolidinediones effectively lowers blood glucose in type 2 diabetes patients. This combination therapy offers a valuable approach for managing T2DM when other treatments fall short.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gestational diabetes mellitus and life assurance: the United Kingdom perspective.

Diabetic medicine : a journal of the British Diabetic Association·2015
Same author

KLF17 empowers TGF-β/Smad signaling by targeting Smad3-dependent pathway to suppress tumor growth and metastasis during cancer progression.

Cell death & disease·2015
Same author

Second-trimester intra-abdominal bowel dilation in fetuses with gastroschisis predicts neonatal bowel atresia.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2006
Same author

The putative collagen binding peptide hastens periodontal ligament cell attachment to bone replacement graft materials.

Journal of periodontology·2001
Same author

Gingival, dermal, and periodontal ligament fibroblasts express different extracellular matrix receptors.

Journal of periodontology·2001
Same author

A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes.

Expert opinion on pharmacotherapy·2001
Same journal

Pancreas procurement from multiorgan donors for islet trasplantation.

Diabetes, nutrition & metabolism·2011
Same journal

Outcome of human islet isolation and allotransplantation in 20 consecutive cases.

Diabetes, nutrition & metabolism·2011
Same journal

Resting metabolic rate incremented by pulsating electrostatic field (PESF) therapy.

Diabetes, nutrition & metabolism·2005
Same journal

Effectiveness of an uninterrupted procedure to transfer adolescents with Type 1 diabetes from the Paediatric to the Adult Clinic held in the same hospital: eight-year experience with the Parma protocol.

Diabetes, nutrition & metabolism·2005
Same journal

Prevalence of obstructive sleep apnoea in a sample of obese women: effect of menopause.

Diabetes, nutrition & metabolism·2005
Same journal

Associations among sex hormone binding globulin concentrations and characteristics of the metabolic syndrome in obese women.

Diabetes, nutrition & metabolism·2005
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus (T2DM) is a progressive condition characterized by declining insulin secretion and rising insulin resistance.
  • Initial management with diet and lifestyle changes is often insufficient, necessitating pharmacological intervention.
  • As T2DM progresses, monotherapy becomes less effective, requiring combination therapies with complementary mechanisms of action.

Purpose of the Study:

  • To evaluate the efficacy of repaglinide in combination with other antidiabetic agents.
  • To assess repaglinide's role in improving glycemic control in patients with inadequately managed T2DM.

Main Methods:

  • Repaglinide was studied in combination with metformin, neutral protamine Hagedorn (NPH)-insulin, and three thiazolidinediones (TZDs).

Related Experiment Videos

  • Patient populations included those whose diabetes was not adequately controlled by prior monotherapy or combination therapy.

    • Main Results:

    • Repaglinide plus metformin reduced fasting plasma glucose by 2.2 mmol/l and HbA1c by 1.4%.
    • Repaglinide plus NPH-insulin reduced fasting plasma glucose by 5.4 mmol/l and HbA1c by 0.7%.
    • Repaglinide combined with each TZD also demonstrated consistent reductions in fasting plasma glucose and HbA1c, with no severe hypoglycemia reported.

    Conclusions:

    • Repaglinide exhibits additive and synergistic effects on glycemic control when used in combination regimens.
    • Repaglinide represents a valuable therapeutic option for managing type 2 diabetes mellitus, particularly in combination therapies.